NDA 217202 · Aop Hlth US
Rapiblyk
Landiolol Hydrochloride · Intravenous
NovelCDER novel approval, Nov 22, 2024: To treat supraventricular tachycardia
Last checked: Nov 21, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Nov 22, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
16
7 Phase 3, 4 recruiting
FAERS reports
84
81 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 19, 2026.
RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia. RAPIBLYK is a beta adrenergic blocker indicated for the short-term reduction of ventricular rate in: adults with supraventricular tachycardia including atrial fibrillation and atrial flutter ( 1 ), and pediatric patients with supraventricular tachycardia.( 1 )
Mechanism: RAPIBLYK is a selective beta-1-adrenoreceptor antagonist that inhibits the positive chronotropic effects of the catecholamines, epinephrine and norepinephrine, on the heart, where beta-1-receptors are predominantly located. Landiolol does not exhibit any membrane-stabilizing activity or intrinsic sympathomimetic activity at the approved recommended dosage in vitro.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 13, 2026 Supplement 1 · Efficacy LetterLabel
- Nov 22, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- RAPIBLYK · LANDIOLOL HYDROCHLORIDE EQ 280MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Landiolol" as an intervention, any sponsor and status, largest first.
- Landiolol in Mitral Valve SurgeryPivotal-lookingRecruiting
Università Vita-Salute San RaffaeleAcademic, hospital or other
NCT06793670 · 1,500 participants (planned) · Start Jan 28, 2025 · Primary completion Jun 2027
Drug: Landiolol; Placebo · For: Cardiac Failure; Low Cardiac Output Syndrome
Sites: Alessandria, Italy; Torino, Italy; Catania, Italy · 13 sites in all
- Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac SurgeryPivotal-lookingCompleted
CMC Ambroise ParéAcademic, hospital or other
NCT04607122 · 400 participants · Start Jan 27, 2021 · Primary completion Jun 30, 2023
Drug: Landiolol; Saline · For: Atrial Fibrillation; Cardiac Surgery
Sites: Massy, France; Neuilly-sur-Seine, France; Saint-Denis, France
- Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac SurgeryPivotal-lookingStatus unknown
University Hospital, CaenAcademic, hospital or other
NCT04223739 · 380 participants (planned) · Start Dec 13, 2019 · Primary completion Jun 1, 2021
Drug: Landiolol; Amiodarone · For: Atrial Fibrillation; Cardiac Surgery
Sites: Caen, France
- Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With HypercontractilityPivotal-lookingRecruiting
Centre Hospitalier Universitaire, AmiensAcademic, hospital or other
NCT04748796 · 360 participants (planned) · Start Feb 1, 2021 · Primary completion Jun 2027
Drug: Landiolol · For: Septic Shock; Tachycardia; Mortality During Septic Shock and 1 more
Sites: Amiens, France
- Study of ONO-1101 in Patients Scheduled for Multi-Slice Computed Tomography (CT)Pivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT00924586 · 258 participants · Start Jun 2009 · Primary completion Feb 2010
Drug: ONO-1101; ONO-1101 · For: Coronary Artery Disease
Sites: Kanto, Japan; Kyushu, Japan
- Study of ONO-1101 in Patients Scheduled for Coronary AngiographyPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT00560209 · 183 participants · Start Nov 2007 · Primary completion Nov 2008
Drug: ONO-1101; ONO-1101 and 1 more · For: Coronary Artery Disease
Sites: Kinki, Japan
- Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in JapanPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT00212654 · 165 participants · Start Jun 2001 · Primary completion Apr 2006
Drug: ONO-1101 · For: Postoperative Supraventricular Tachyarrythmia
- Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac SurgeryPivotal-lookingStatus unknown
Medical University of ViennaAcademic, hospital or other
NCT05084118 · 164 participants (planned) · Start Oct 21, 2021 · Primary completion Nov 1, 2023
Drug: Landiolol HCl; Placebo · For: Atrial Fibrillation; Postoperative Complications
Sites: Vienna, Austria
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective35
- off label use12
- bradycardia8
- ventricular fibrillation7
- condition aggravated6
- drug ineffective for unapproved indication6
- atrial fibrillation5
- cardiac failure5
- hypotension5
- product use in unapproved indication5
- cardiogenic shock4
- electrocardiogram qt prolonged4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 12 |
| 2022 | 25 |
| 2024 | 14 |
| 2025 | 9 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP).
Rehberg S, Frank S, Černý V, et al. · Intensive Care Med 2024 · Randomized Controlled Trial, Multicenter Study
- Comparison of Esmolol Versus Landiolol on Mortality in Adult Patients With Sepsis: A Systematic Review and Network Meta-Analysis.
Tang Z, Sun Q, Xu J, et al. · Crit Care Med 2026 · Systematic Review, Meta-Analysis
- Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
Kakihana Y, Nishida O, Taniguchi T, et al. · Lancet Respir Med 2020 · Multicenter Study, Randomized Controlled Trial
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Mortality in septic patients treated with short-acting betablockers: a comprehensive meta-analysis of randomized controlled trials.
Alexandru MG, Niewald P, Krüger S, et al. · Crit Care 2024 · Meta-Analysis
- Mortality in Patients With Sepsis Treated With Esmolol or Landiolol: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis.
Sato R, Messina S, Hasegawa D, et al. · Chest 2025 · Systematic Review, Meta-Analysis
Sponsor: Aop Hlth US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.